The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Nomonde Ngema, 21, who was born with HIV, not only tackles the stigma on TikTok by sharing her journey, she also takes on ...

根据在2024年IDWeek上展示的研究结果，ibalizumab更频繁地被选用于晚期HIV患者，大多数受试者保持治疗超过两年，显示出持久性。该研究旨在为这组经常面临多重耐药问题的患者群体提供长期临床结果和影响病毒学控制的因素的见解。

关于DT的数据当下甚少，且部分结果相互矛盾，多数缺乏对照组。专家意见认为DT可能对患者的预后产生负面影响。因此，西班牙罗西奥圣母医院进行了一项随机临床试验，旨在通过长达96周的全面评估，对IR、IA/I、细胞相关HIV-DNA（CA-DNA）与未剪接 ...

New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...